Trailblazing the path to transcription factors by intervening at a previously hidden region we have identified as the ‘switch site.’



To date, the collective research on transcription factors has been elusive to drug discovery. However, Flare Therapeutics has now reached a moment of light – with the prospect of forever changing the trajectory of how we treat disease.



Flare’s pipeline is Initially focused on precision oncology.

Our small molecules are designed to regain transcriptional control that is hijacked by cancer.




Intensity, empathy, determination, and brilliance. The Flare Therapeutics team is a living, growing, thriving organization of talented people and bright minds. We are always looking for new sparks to flame our collective fire. Learn more about our culture and join us!

  Join Us

Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Led by GordonMD® Global Investments LP and Pfizer Ventures, financing to support advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare’s platform and pipeline of novel transcription factor targets in oncology

  Read full story


This links to an external website.